Last 12 months
Inside the activity.
0 purchase rows · 83 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 31 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 27 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 8 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2024 Filed Mar 20, 2024 00:30 UTC |
Kaye Edward M. MDDirector · CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008683 · form4-03202024_120318.xml · derivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,500 Underlying: Common Stock · 35,500 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The award vested or vests as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:30 UTC |
Kaye Edward M. MDDirector · CEO
|
Exercise / conversionCommon Stock | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008683 · form4-03202024_120318.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:31 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionRestricted Stock Units · Derivative | 13,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008686 · form4-03202024_120349.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,300 Underlying: Common Stock · 13,100 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The award vested or vests as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:31 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionCommon Stock | 13,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008686 · form4-03202024_120349.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reported total includes an aggregate 2,345 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:29 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
Exercise / conversionRestricted Stock Units · Derivative | 7,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008681 · form4-03202024_120354.xml · derivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,425 Underlying: Common Stock · 7,475 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The award vested or vests as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:29 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
Exercise / conversionCommon Stock | 7,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008681 · form4-03202024_120354.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reported total includes an aggregate 2,598 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:21 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,504 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001415889-24-006623 · form4-03052024_090335.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,442 Underlying: Common Stock · 5,504 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:21 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
SaleCommon Stock | 10,000 | $7.75 | $77,469.00 |
DisclosureSEC source: 0001415889-24-006623 · form4-03052024_090335.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,485 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.50 to $7.93 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:21 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
Exercise / conversionCommon Stock | 5,504 | $0.60 | $3,302.40 |
DisclosureSEC source: 0001415889-24-006623 · form4-03052024_090335.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:17 UTC |
TZIANABOS ARTHURDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 31,739 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001415889-24-003897 · form4-02152024_090236.xml · derivative · entry 2 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,739 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This fully-vested option award vested as to 1/48th of the total award on October 4, 2018 with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:17 UTC |
TZIANABOS ARTHURDirector
|
Exercise / conversionCommon Stock | 31,739 | $2.19 | $69,508.41 |
DisclosureSEC source: 0001415889-24-003897 · form4-02152024_090236.xml · nonDerivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:32 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
SaleCommon Stock | 10,000 | $4.80 | $47,991.00 |
DisclosureSEC source: 0001415889-24-002531 · form4-02052024_090232.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,981 F1 · kind: The sale reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.59 to $4.95 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:38 UTC |
Ticho BarryChief Medical Officer
|
SaleCommon Stock | 10,000 | $5.74 | $57,352.00 |
DisclosureSEC source: 0001209191-24-000801 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,981 F1 · kind: The sale reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.15 to $5.97 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The reported total includes an additional 1,086 shares of the issuer's stock that were acquired by the reporting person through the issuer's employee stock purchase plan in exempt transactions pursuant to Rule 16b3(c). Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:18 UTC |
Ticho BarryChief Medical Officer
|
GrantRestricted Stock Unit (RSU) · Derivative | 60,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057407 · doc4.xml · derivative · entry 4 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,773 Underlying: Common Stock · 60,773 shares Expires 2025-12-01 F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: 48,792 restricted stock units will vest on December 1, 2024 and 11,981 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:18 UTC |
Ticho BarryChief Medical Officer
|
Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 107,400 | Not disclosed Strike: $20.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-057407 · doc4.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,400 shares Expires 2032-03-14 F6 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 107,400 shares of Common Stock of the Issuer and in exchange issued to the reporting person 33,561 restricted stock units. F5 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 15, 2022 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:18 UTC |
Ticho BarryChief Medical Officer
|
Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 65,600 | Not disclosed Strike: $60.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-057407 · doc4.xml · derivative · entry 2 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,600 shares Expires 2031-03-01 F4 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 65,600 shares of Common Stock of the Issuer and in exchange issued to the reporting person 8,463 restricted stock units. F3 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 2, 2021 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:18 UTC |
Ticho BarryChief Medical Officer
|
Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $20.25 | Not disclosed |
DisclosureSEC source: 0001209191-23-057407 · doc4.xml · derivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2030-03-24 F2 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 60,000 shares of Common Stock of the Issuer and in exchange issued to the reporting person 18,749 restricted stock units. F1 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 25, 2020 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:20 UTC | GrantRestricted Stock Unit (RSU) · Derivative | 60,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057410 · doc4.xml · derivative · entry 4 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,773 Underlying: Common Stock · 60,773 shares Expires 2025-12-01 F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: 48,792 restricted stock units will vest on December 1, 2024 and 11,981 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document |
|
| December 01, 2023 Filed Dec 5, 2023 21:20 UTC | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 107,400 | Not disclosed Strike: $20.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-057410 · doc4.xml · derivative · entry 3 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,400 shares Expires 2032-03-14 F6 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 107,400 shares of Common Stock of the Issuer and in exchange issued to the reporting person 33,561 restricted stock units. F5 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 15, 2022 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
|
| December 01, 2023 Filed Dec 5, 2023 21:20 UTC | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 65,600 | Not disclosed Strike: $60.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-057410 · doc4.xml · derivative · entry 2 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,600 shares Expires 2031-03-01 F4 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 65,600 shares of Common Stock of the Issuer and in exchange issued to the reporting person 8,463 restricted stock units. F3 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 2, 2021 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
|
| December 01, 2023 Filed Dec 5, 2023 21:20 UTC | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $20.25 | Not disclosed |
DisclosureSEC source: 0001209191-23-057410 · doc4.xml · derivative · entry 1 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2030-03-24 F2 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 60,000 shares of Common Stock of the Issuer and in exchange issued to the reporting person 18,749 restricted stock units. F1 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 25, 2020 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
|
| December 01, 2023 Filed Dec 5, 2023 21:17 UTC |
Nash Huw M.COO & CBO
|
GrantRestricted Stock Unit (RSU) · Derivative | 8,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057403 · doc4.xml · derivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,463 Underlying: Common Stock · 8,463 shares Expires 2025-12-01 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: 7,053 restricted stock units will vest on December 1, 2024 and 1,410 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:17 UTC |
Nash Huw M.COO & CBO
|
Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 65,600 | Not disclosed Strike: $60.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-057403 · doc4.xml · derivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,600 shares Expires 2031-03-01 F2 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 65,600 shares of Common Stock of the Issuer and in exchange issued to the reporting person 8,463 restricted stock units. F1 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 2, 2021 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:15 UTC |
Kaye Edward M. MDDirector · CEO
|
GrantRestricted Stock Unit (RSU) · Derivative | 25,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057396 · doc4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,908 Underlying: Common Stock · 25,908 shares Expires 2025-12-01 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: 21,591 restricted stock units will vest on December 1, 2024 and 4,317 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:15 UTC |
Kaye Edward M. MDDirector · CEO
|
Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 200,800 | Not disclosed Strike: $60.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-057396 · doc4.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,800 shares Expires 2031-03-01 F2 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 200,800 shares of Common Stock of the Issuer and in exchange issued to the reporting person 25,908 restricted stock units. F1 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 2, 2021 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:09 UTC |
Allan JonathanGeneral Counsel & Corp Sec
|
GrantRestricted Stock Unit (RSU) · Derivative | 46,284 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057387 · doc4.xml · derivative · entry 3 Allan Jonathan · CIK 0001966716 · General Counsel & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,284 Underlying: Common Stock · 46,284 shares Expires 2025-12-01 F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: 33,927 restricted stock units will vest on December 1, 2024 and 12,357 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:09 UTC |
Allan JonathanGeneral Counsel & Corp Sec
|
Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 121,100 | Not disclosed Strike: $20.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-057387 · doc4.xml · derivative · entry 2 Allan Jonathan · CIK 0001966716 · General Counsel & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121,100 shares Expires 2032-03-14 F4 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 121,100 shares of Common Stock of the Issuer and in exchange issued to the reporting person 37,843 restricted stock units. F3 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 15, 2022 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:09 UTC |
Allan JonathanGeneral Counsel & Corp Sec
|
Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 65,000 | Not disclosed Strike: $59.84 | Not disclosed |
DisclosureSEC source: 0001209191-23-057387 · doc4.xml · derivative · entry 1 Allan Jonathan · CIK 0001966716 · General Counsel & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2031-02-15 F2 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 65,000 shares of Common Stock of the Issuer and in exchange issued to the reporting person 8,441 restricted stock units. F1 · derivative.exercise_date: The canceled option vested as to 1/4th of the total award on February 16, 2022, and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 20:48 UTC |
SMITH IAN FDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 96,340 | $0.00 Strike: $4.76 | $0.00 |
DisclosureSEC source: 0001209191-23-050170 · doc4.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,340 Underlying: Common Stock · 96,340 shares Expires 2033-09-18 F1 · derivative.exercise_date: The option vests ratably as to 1/12th of the total award on December 19, 2023, with 1/12th of the total award vesting quarterly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 21:20 UTC |
Ticho BarryChief Medical Officer
|
SaleCommon Stock | 15,000 | $10.60 | $158,973.00 |
DisclosureSEC source: 0001209191-23-041616 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,895 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 17, 2022 by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.28 to $10.77 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:45 UTC |
Allan JonathanGeneral Counsel & Corp Sec
|
SaleCommon Stock | 1,948 | $13.48 | $26,252.22 |
DisclosureSEC source: 0001209191-23-039428 · doc4.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · General Counsel & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 22, 2023 by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.21 to $13.90 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:24 UTC |
Krainer Adrian R.Director
|
GrantDirector Stock Option (Right to Buy) · Derivative | 19,441 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-23-037532 · doc4.xml · derivative · entry 1 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,441 Underlying: Common Stock · 19,441 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:24 UTC |
LEVIN ARTHUR ADirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 19,441 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-23-037533 · doc4.xml · derivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,441 Underlying: Common Stock · 19,441 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:26 UTC |
TZIANABOS ARTHURDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 19,441 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-23-037539 · doc4.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,441 Underlying: Common Stock · 19,441 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:26 UTC |
Smith JulieDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 19,441 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-23-037537 · doc4.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,441 Underlying: Common Stock · 19,441 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:25 UTC |
Menzel Garry EDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 19,441 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-23-037535 · doc4.xml · derivative · entry 1 Menzel Garry E · CIK 0001556064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,441 Underlying: Common Stock · 19,441 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:23 UTC |
Harrison Seth LoringDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 19,441 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-23-037530 · doc4.xml · derivative · entry 1 Harrison Seth Loring · CIK 0001404955 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,441 Underlying: Common Stock · 19,441 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:22 UTC |
Burstein JenniferDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 19,441 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-23-037529 · doc4.xml · derivative · entry 1 Burstein Jennifer · CIK 0001640069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,441 Underlying: Common Stock · 19,441 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 23:31 UTC |
Ticho BarryChief Medical Officer
|
SaleCommon Stock | 15,000 | $11.13 | $166,963.50 |
DisclosureSEC source: 0001209191-23-034648 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,895 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 17, 2022 by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.62 to $11.36 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2023 Filed May 8, 2023 23:35 UTC |
Ticho BarryChief Medical Officer
|
SaleCommon Stock | 653 | $10.00 | $6,530.00 |
DisclosureSEC source: 0001209191-23-028111 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,895 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 17, 2022 by the reporting person. Read SEC document |
| May 03, 2023 Filed May 4, 2023 00:04 UTC |
Ticho BarryChief Medical Officer
|
SaleCommon Stock | 24,697 | $10.14 | $250,365.84 |
DisclosureSEC source: 0001209191-23-027190 · doc4.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,548 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 17, 2022 by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.37 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 02, 2023 Filed May 4, 2023 00:04 UTC |
Ticho BarryChief Medical Officer
|
SaleCommon Stock | 5,513 | $10.00 | $55,133.86 |
DisclosureSEC source: 0001209191-23-027190 · doc4.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,245 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 17, 2022 by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.02 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2023 Filed May 4, 2023 00:04 UTC |
Ticho BarryChief Medical Officer
|
SaleCommon Stock | 24,967 | $10.00 | $249,767.37 |
DisclosureSEC source: 0001209191-23-027190 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,758 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 17, 2022 by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.07 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 27, 2023 Filed Sep 8, 2023 20:15 UTC |
Kaye Edward M. MDDirector · CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-23-048770 · doc4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,801 Underlying: Common Stock · 20,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on October 17, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 27, 2023 Filed Sep 8, 2023 20:15 UTC |
Kaye Edward M. MDDirector · CEO
|
Exercise / conversionCommon Stock | 20,000 | $0.60 | $12,000.00 |
DisclosureSEC source: 0001209191-23-048770 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:35 UTC |
Ticho BarryChief Medical Officer
|
GrantRestricted Stock Unite (RSU) · Derivative | 52,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019662 · doc4.xml · derivative · entry 2 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,400 Underlying: Common Stock · 52,400 shares Expires 2027-03-15 F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:35 UTC |
Ticho BarryChief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 78,600 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001209191-23-019662 · doc4.xml · derivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,600 Underlying: Common Stock · 78,600 shares Expires 2033-03-14 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 15, 2023 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:37 UTC |
Allan JonathanGeneral Counsel & Corp Sec
|
GrantRestricted Stock Unit (RSU) · Derivative | 29,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019676 · doc4.xml · derivative · entry 2 Allan Jonathan · CIK 0001966716 · General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,900 Underlying: Common Stock · 29,900 shares Expires 2027-03-15 F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:37 UTC |
Allan JonathanGeneral Counsel & Corp Sec
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 44,800 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001209191-23-019676 · doc4.xml · derivative · entry 1 Allan Jonathan · CIK 0001966716 · General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,800 Underlying: Common Stock · 44,800 shares Expires 2033-03-14 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 15, 2023 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:36 UTC | GrantRestricted Stock Unit (RSU) · Derivative | 52,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019669 · doc4.xml · derivative · entry 2 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,400 Underlying: Common Stock · 52,400 shares Expires 2027-03-15 F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.